Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 2/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6245903 | 0.98 | KCNA3 (0.64) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL23151885 | 0.98 | KCNA3 (0.64) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL5683038 | 0.84 | KCNA3 (0.61) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL5679133 | 0.84 | KCNA3 (0.61) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL5682884 | 0.82 | KCNA3 (0.59) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL5679061 | 0.82 | KCNA3 (0.59) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL1490164 | 0.82 | KCNA3 (1.00) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL5681069 | 0.81 | KCNA3 (0.57) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL5679065 | 0.81 | KCNA3 (0.57) | KCNA3TAAR1HDAC3HDAC4HDAC1 | |
| SCHEMBL9307905 | 0.80 | KCNA3 (0.61) | KCNA3TAAR1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112194791-A | Transparent polyimide film and preparation method thereof | 中国科学院长春应用化学研究所 | 2021-01-08 | — | — | CN | claimed |
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-10 | — | — | US | disclosed |
| US-7566808-B2 | Management of ophthalmologic disorders, including macular degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-24 | — | — | US | disclosed |
| EP-1919858-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | The President and Fellows of Harvard College (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007019503-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1722766-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-30 | — | — | US | disclosed |
| WO-2005079774-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | KCNA3 1535/4885TAAR1 2723/4885HDAC3 1075/4885 |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | KCNA3 1929/4885TAAR1 3005/4885HDAC3 1051/4885 |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | ALDH1A2, PDE6C, PDE6B | KCNA3 2044/4885TAAR1 2679/4885HDAC3 1217/4885 |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PDE6C, PDE6A, ALDH1A2 | KCNA3 1313/4885TAAR1 2328/4885HDAC3 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.